A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of ADG20 in the Treatment of Ambulatory Participants with Mild or Moderate COVID-19 (STAMP) : A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of ADG20 in the Treatment of Ambulatory Participants with Mild or Moderate COVID-19 (STAMP)

Medienart:

Klinische Studie

Erscheinungsjahr:

2022

Erschienen:

2022

Enthalten in:

WHO International Clinical Trials Registry Platform - (2022) vom: 01. Feb. Zur Gesamtaufnahme - year:2022

Sprache:

Englisch

Links:

Volltext [kostenfrei]

Themen:

610
Medical Condition: COVID-19 MedDRA version: 23.0Level: LLTClassification code 10084382Term: Coronavirus disease 2019System Organ Class: 100000004862;Therapeutic area: Diseases [C] - Virus Diseases [C02]
Phase: Phase 2
Recruitment Status: Not yet recruiting
Study Type: Interventional

Anmerkungen:

WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 15-06-2021, Last updated: 2022-11-24

ICTRP ID:

EUCTR2020-006082-11-BG
ADG20-TRMT-001
2020-006082-11-GR

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

WHO007873913